tradingkey.logo

US FDA warns 30 telehealth firms over misleading marketing of compounded GLP‑1 drugs

ReutersMar 3, 2026 6:42 PM

- The U.S. Food and Drug Administration has warned 30 telehealth companies for making false or misleading claims about compounded versions of GLP‑1 drugs, the agency said on Tuesday.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI